- Home
- CRSP vs PRCT Comparison
CRSP vs PRCT Comparison
Compare CRSP & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- PRCT
- Stock Information
- Founded
- CRSP 2013
- PRCT 2009
- Country
- CRSP Switzerland
- PRCT United States
- Employees
- CRSP N/A
- PRCT N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- PRCT Medical Specialities
- Sector
- CRSP Health Care
- PRCT Health Care
- Exchange
- CRSP Nasdaq
- PRCT Nasdaq
- Market Cap
- CRSP 3.4B
- PRCT 2.9B
- IPO Year
- CRSP 2016
- PRCT 2021
- Fundamental
- Price
- CRSP $37.77
- PRCT $53.03
- Analyst Decision
- CRSP Buy
- PRCT Strong Buy
- Analyst Count
- CRSP 19
- PRCT 7
- Target Price
- CRSP $74.35
- PRCT $91.43
- AVG Volume (30 Days)
- CRSP 2.4M
- PRCT 1.0M
- Earning Date
- CRSP 05-07-2025
- PRCT 04-24-2025
- Dividend Yield
- CRSP N/A
- PRCT N/A
- EPS Growth
- CRSP N/A
- PRCT N/A
- EPS
- CRSP N/A
- PRCT N/A
- Revenue
- CRSP $37,314,000.00
- PRCT $224,498,000.00
- Revenue This Year
- CRSP $51.35
- PRCT $46.28
- Revenue Next Year
- CRSP $282.16
- PRCT $32.67
- P/E Ratio
- CRSP N/A
- PRCT N/A
- Revenue Growth
- CRSP N/A
- PRCT 64.84
- 52 Week Low
- CRSP $30.04
- PRCT $47.04
- 52 Week High
- CRSP $67.88
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- CRSP 49.46
- PRCT 42.69
- Support Level
- CRSP $36.74
- PRCT $51.27
- Resistance Level
- CRSP $40.13
- PRCT $54.75
- Average True Range (ATR)
- CRSP 2.67
- PRCT 3.64
- MACD
- CRSP 0.72
- PRCT 0.19
- Stochastic Oscillator
- CRSP 76.62
- PRCT 49.48
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.